It’s about TIME – Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by an extremely poor prognosis and limited therapeutic options. Central to the progression and immune evasion of PDAC is the tumor (immune) microenvironm…